Randomized Phase II Trial of Temsirolimus (NCI-Supplied Agent, NSC 683864, IND 61010) or the Combination of Hormonal Therapy Plus Temsirolimus in Women With Advanced, Persistent, or Recurrent Endometrial Carcinoma.
Phase of Trial: Phase II
Latest Information Update: 17 Apr 2017
At a glance
- Drugs Temsirolimus (Primary) ; Megestrol; Tamoxifen
- Indications Endometrial cancer
- Focus Therapeutic Use
- 11 Apr 2017 Status changed from active, no longer recruiting to completed.
- 02 Aug 2016 Planned primary completion date changed from 1 Jul 2016 to 1 Jan 2017.
- 27 Jul 2015 According to the ClinicalTrials.gov record, planned end date changed to 1 Jul 2016.